Plasmid DNA CDMOs — Ranked by Signal Score · 2026
· updated as new inspection, certificate, and trial data enters the platform
22
CDMOs tracked
22
Fully scored
9
With FDA records
35
FDA inspections
113
EMA/MHRA GMP certs
2
Warning letters
Shortlist plasmid DNA CDMOs with Signal
CDMO Signal is an independent sourcing platform cell therapy, gene therapy, and mRNA sponsors use to compare and shortlist plasmid DNA CDMOs before an RFI. This page is the entry point — the ranked table below is derived from FDA inspection history, EMA/MHRA GMP certificate density, ClinicalTrials.gov sponsor and program footprint, and monitored capacity signals. Use it to narrow the field, then verify fermentation scale, purity specifications, endotoxin control, and lead time directly with the shortlisted suppliers — especially when plasmid is on your program's critical path for viral vector or mRNA supply.
- Compare plasmid DNA CDMOs side-by-side on FDA inspection history, EMA/MHRA GMP certificate density, ClinicalTrials.gov sponsor and program footprint, and monitored capacity signals — every number traceable to primary sources.
- Filter by regulatory jurisdiction, clean-inspection posture, and clinical-program breadth to your program's shortlisting criteria.
- Shortlist Use the ranked results to build your shortlist, then open each profile to review the underlying evidence before contacting suppliers. Follow up with the shortlisted CDMOs to verify fermentation scale, purity specifications, endotoxin control, and lead time directly.
Plasmid DNA is the upstream starting material for viral vectors, mRNA, and DNA therapeutics — which makes plasmid supply a frequent bottleneck for the entire advanced-therapy pipeline. Plasmid CDMOs run microbial (E. coli) fermentation, alkaline lysis, and chromatographic purification to GMP grade.
Selecting a plasmid CDMO turns on GMP vs research grade, supercoiled fraction and purity, fermentation scale, and lead time. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 15 NAI (no action), 18 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: United States (33), UNITED KINGDOM (31), Germany (29), Austria (11), Belgium (11).
Last updated 2026-10-06. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
TF
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
|
81.0 | 100.0 | 6 insp · 10 GMP | Available | 2 programs |
| 2 |
OX
Oxford Biomedica
Oxford, United Kingdom
|
76.2 | 100.0 | 0 insp · 13 GMP | Available | 7 programs |
| 3 |
CR
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
90.9 | 98.3 | 8 insp · 11 GMP | Limited | 0 programs |
| 4 |
RP
ReciBioPharm
Keele, UK · Sodertalje, SE
|
88.0 | 100.0 | 0 insp · 3 GMP | — | 0 programs |
| 5 |
PB
Pharmaron Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
|
86.9 | 100.0 | 3 insp · 0 GMP | Available | 0 programs |
| 6 |
AE
Aldevron
Fargo, ND
|
84.8 | 100.0 | 1 insp · 0 GMP | — | 0 programs |
| 7 |
KB
KBI Biopharma
Durham, NC · Boulder, CO
|
84.4 | 99.1 | 1 insp · 1 GMP | Limited | 0 programs |
| 8 |
RB
Richter BioLogics
Hamburg, Germany
|
82.9 | 100.0 | 0 insp · 9 GMP | — | 0 programs |
| 9 |
WK
Wacker Biotech
Jena, DE · Amsterdam, NL · San Diego, CA
|
81.6 | 100.0 | 0 insp · 13 GMP | — | 0 programs |
| 10 |
KE
Kaneka Eurogentec
Seraing, BE
|
80.3 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 11 |
Cytovance Biologics
Oklahoma City, OK
|
78.6 | 98.1 | 1 insp · 0 GMP | Available | 0 programs |
| 12 |
AA
Ascend Advanced Therapies
London, United Kingdom
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 13 |
BM
Biomay AG
Vienna, Austria
|
76.3 | 98.9 | 2 insp · 11 GMP | — | 0 programs |
| 14 |
Catalent
Bagsværd, Denmark (operating under Novo Holdings)
|
73.1 | 74.9 | 12 insp · 37 GMP | — | 0 programs |
| 15 |
CA
Catalent (Novo Holdings)
Harmans, MD · Gosselies, BE
|
73.1 | 74.9 | 1 insp · 0 GMP | Available | 0 programs |
| 16 |
AN
Andelyn Biosciences
Columbus, OH
|
63.0 | — | — | Available | 0 programs |
| 17 |
BN
Bionova Scientific
Fremont, CA
|
59.0 | — | — | — | 0 programs |
| 18 |
HX
Helixmith
Seoul, KR
|
59.0 | — | — | — | 0 programs |
| 19 |
UB
uBriGene Biosciences
Shanghai, CN · Boston, MA
|
56.5 | — | — | — | 0 programs |
| 20 |
NE
Nature Technology
Lincoln, NE
|
56.5 | — | — | — | 0 programs |
| 21 |
VX
VGXI
The Woodlands, TX
|
56.5 | — | — | — | 0 programs |
| 22 |
PF
PlasmidFactory
Bielefeld, Germany
|
56.5 | — | — | — | 0 programs |
What to evaluate in a Plasmid DNA CDMO
GMP grade & purity
Confirm GMP (vs research/HQ) grade, supercoiled percentage, and residual host-cell DNA/RNA and endotoxin specs — these gate downstream vector and mRNA quality.
Fermentation scale & yield
Match fermentation scale and yield to your vector or mRNA demand. Ask about high-yield strains and whether scale-up is validated.
Lead time
Plasmid is a common critical-path bottleneck. Evaluate realistic queue and turnaround against your program timeline.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
GMP-grade plasmid vs research-grade — how CDMOs differ
GMP-grade plasmid manufacturing is a materially different discipline from research-grade. GMP requires fermentation under controlled conditions with qualified E. coli strains, endotoxin control (typically <0.1 EU/µg), quantified supercoiled content (>90% is a common target), and full release testing per the intended downstream use. Some CDMOs specialize exclusively in GMP grades; others offer both. Sponsors should also distinguish "GMP-source" plasmid (research-grade produced in GMP facilities) from "full GMP" — some early clinical programs can start on GMP-source but almost all late-stage and commercial work requires full GMP with the accompanying documentation package.
Plasmid CDMOs by downstream use case
Plasmid manufacturing serves three different downstream markets, each with different specs. mRNA template plasmids need to be linearizable and are produced at moderate scale — see the mRNA / LNP CDMO ranking for integrated mRNA+plasmid CDMOs. Viral vector production requires transfection-grade plasmid at moderate scale, often as 2- or 3-plasmid systems — see the AAV CDMO ranking and Lentiviral CDMO ranking. Direct gene therapy uses plasmid as the drug substance itself, at the largest scale and with a distinct regulatory profile. CDMOs vary in which use case they've validated for.
Commercial-scale plasmid — who has the depth?
Commercial-scale plasmid demand has grown sharply alongside mRNA and gene therapy programs. The commercial-scale plasmid filter surfaces CDMOs with top-quartile Signal Score. Commercial plasmid requires validated fermentation at 200L+ scale, chromatographic purification without cesium chloride (which does not scale), and demonstrated endotoxin and residual-DNA control at commercial batch sizes. Sponsors should verify not just capacity headroom but the CDMO's inspection record specifically on the plasmid facility, since plasmid GMP is inspection-verified against strict impurity and identity specs.
How CDMO Signal computes the plasmid DNA ranking
The plasmid DNA Signal Score is the platform's standard four-pillar composite. Quality Compliance (35%) leans on FDA inspection classifications, Warning Letter history, and EMA/MHRA GMP certificate density — for plasmid manufacturing this pillar is central, since endotoxin and residual-DNA control are inspection-verified. Operations (25%) reflects ClinicalTrials.gov sponsor and program footprint. Financial Stability (20%) draws on SEC filings and parent-company signals. Capacity Intelligence (20%) tracks monitored trade press for fermentation expansions. Full weightings at cdmosignal.com/methodology.
Plasmid DNA CDMOs — Frequently Asked Questions
Who are the top Plasmid DNA CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Plasmid DNA CDMOs include Thermo Fisher Scientific, Oxford Biomedica, Charles River Laboratories. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Plasmid DNA CDMOs have FDA inspection records?
CDMO Signal tracks 9 Plasmid DNA CDMOs with FDA inspection records and 113 EMA/MHRA GMP certificates across the group.
What should I look for in a plasmid DNA CDMO?
Confirm GMP grade and purity specs (supercoiled %, residual host DNA, endotoxin), fermentation scale and yield for your demand, realistic lead time, and a clean FDA and EMA/MHRA record.
Why is plasmid DNA supply often a bottleneck?
Plasmid is the starting material for viral vectors and mRNA, so a single GMP plasmid lot gates multiple downstream steps. Constrained GMP fermentation capacity and long queues make it a frequent critical-path item.
Related modalities